Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer
Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
This randomized phase II trial is studying how well giving gefitinib together with
anastrozole works compared to giving gefitinib together with fulvestrant in treating
postmenopausal women with recurrent or metastatic breast cancer. Estrogen can stimulate the
growth of breast cancer cells. Hormone therapy using anastrozole and fulvestrant may fight
breast cancer by blocking the use of estrogen. Gefitinib (ZD1839) may stop the growth of
cancer cells by blocking the enzymes necessary for their growth. It is not yet known whether
gefitinib is more effective when combined with anastrozole or fulvestrant in treating breast
cancer.